Results 71 to 80 of about 2,041 (194)

Clinical and laboratorial outcome of different age-onset systemic lupus erythematosus patients in Jiangsu, China: a multicentre retrospective study

Scientific Reports, 2022
Studies on clinical features of systemic lupus erythematosus among different age-onset patients are lacking in China. This multicentre study aimed to systemically compare clinical manifestations, comorbidities, organ involvement, and laboratory findings ...
Lihui Wen, Ziyan Chen, Ziyi Jin, Wenyou Pan, Lin Liu, Min Wu, Fuwan Ding, Huaixia Hu, Xiang Ding, Hua Wei, Yaohong Zou, Xian Qian, Meimei Wang, Jian Wu, Juan Tao, Jun Tan, Zhanyun Da, Miaojia Zhang, Jing Li, Xuebing Feng, Jun Liang, Huayong Zhang, Lingyun Sun   +22 more
doaj   +1 more source

Severe Juvenile-Onset Systemic Lupus Erythematosus: A Case Series-Based Review and Update

Children, 2023
Juvenile-onset systemic lupus erythematosus (jSLE) is a multisystemic disease diagnosed in young patients based on the clinical criteria of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).
Sergi Huerta-Calpe, Ignacio Del Castillo-Velilla, Aida Felipe-Villalobos, Iolanda Jordan, Lluïsa Hernández-Platero   +4 more
doaj   +1 more source

P3 Is there a relationship between lupus anticoagulant autoantibody and fatigue in jSLE? [PDF]

Poster presentations, 2020
Background Fatigue is a common symptom in systemic lupus erythematosus (SLE) and is associated with poorer quality of life and higher depression scores. Lupus anticoagulant (AcL) refers to a subset of autoantibodies to phospholipids interfering with clotting tests, which major clinical association is thrombosis.
Sara Ganhão, Beatriz Silva, Mariana Rodrigues, Francisca Aguiar, Margarida Figueiredo-Braga, Iva Brito   +5 more
openaire   +1 more source

Baricitinib Treatment in RNU7‐1‐Associated Aicardi–Goutières Syndrome in a South African Child: A Case Report

American Journal of Medical Genetics Part A, Volume 197, Issue 5, May 2025.
ABSTRACT Aicardi–Goutières syndrome (AGS) is a rare monogenic type I interferonopathy. Janus kinase (JAK) inhibition has emerged as a potential treatment for AGS. RNU7‐1 is one of the most recently discovered genes for AGS, and the clinical effects of JAK inhibition in these patients have not been reported. Here, we describe the diagnosis and treatment
Timothy F. Spracklen, Shehnaaz Akhalwaya, Sally Ackermann, Carolina Uggenti, Luis Seabra, Yanick J. Crow, Kate Webb   +6 more
wiley   +1 more source

Neuropsychiatric Involvement in Juvenile‐Onset Systemic Lupus Erythematosus

Neurology Research International, Volume 2018, Issue 1, 2018., 2018
Objective. Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by multisystem involvement, including the nervous system. In the present study, we aimed to assess neuropsychiatric manifestations in juvenile‐onset systemic lupus erythematosus (JSLE) in Iran. Methods.
Mohammad-Amin Khajezadeh, Gholamreza Zamani, Bobak Moazzami, Zahra Nagahi, Mahdie Mousavi-Torshizi, Vahid Ziaee, Mamede de Carvalho   +6 more
wiley   +1 more source

Modern treatment options for systemic lupus erythematosus in children (literature review)

Современная ревматология
The treatment of juvenile-onset systemic lupus erythematosus (jSLE) is a complex task in view of the diversity of clinical manifestations and the course of the disease as well as the high risk of organ damage.
M. I. Kaleda, I. P. Nikishina
doaj   +1 more source

Juvenile systemic lupus erythematosus presenting only as nonscarring alopecia

Indian Journal of Paediatric Dermatology, 2022
Juvenile onset systemic lupus erythematosus (JSLE) is a rare multisystem, autoimmune disorder. Alopecia in SLE generally follows a pre-established disease with systemic symptoms. A 13-year-old girl presented with sudden hair loss over the vertex of scalp
N M Vinitha, Reena Rai, G Uma Maheswari
doaj   +1 more source

The development and assessment of biological treatments for children [PDF]

, 2014
The development of biological agents with specific immunological targets has revolutionized the treatment of a wide variety of paediatric diseases where traditional immunosuppressive agents have been partly ineffective or intolerable.
Akobeng, Alexeeva, Alvarez, Andborn, Anink, Baldassano, Biester, Borker, Bout-Tabaku, Braun, Brennan, Brunner, Callen, Caorsi, Cezard, Choueiter, Choy, Cleary, Colombel, Crandall, De Benedetti, De Benedetti, De Cassan, Eberhard, Eleftheriou, Feagan, Fernandes, Fleischmann, Furie, Gasparetto, Gattorno, Gerloni, Giannini, Giannini, Hanauer, Hashkes, Horneff, Horneff, Horneff, Horneff, Horneff, Horneff, Hyams, Hyams, Hyams, Irvine, Jansson, Kahn, Kanakoudi-Tsakalidou, Kaneko, Kavanaugh, Kingsbury, Kok, Kuemmerle-Deschner, Kusuhara, Kutukculer, Lehman, Lehman, Lepore, Lequerre, Lin, Lofgren, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Lowite, Luu, Mangge, Mohler, Munro, Myers, Navarra, Nigrovic, Otten, Paller, Papsdorf, Podolskaya, Prince, Prince, Quartier, Quartier, Quatrier, Robinson, Rosenbach, Rosh, Rothner, Ruemmele, Runner, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Russell, Sakallioglu, Sandborn, Sandborn, Simard, Simonini, Southwood, Swart, Taylor, Toussi, Tynjala, Uperto, Vermeire, Viola, Wallace, Walters, Willems, Wyneski, Yokota, Yokota, Zannin, Zeft, Zulian   +118 more
core   +1 more source

Antibodies against endogenous retroviruses

Immunological Reviews, Volume 328, Issue 1, Page 300-313, November 2024.
Summary The human genome harbors hundreds of thousands of integrations of ancient retroviruses, amassed over millions of years of evolution. To reduce further amplification in the genome, the host prevents transcription of these now endogenous retroviruses (ERVs) through epigenetic repression and, with evolutionary time, ERVs are incapacitated by ...
Mihaela Chisca, Jean‐David Larouche, Qi Xing, George Kassiotis   +3 more
wiley   +1 more source

Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept [PDF]

, 2017
The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients.
A. Civino, A. Consolaro, A. De Fanti, A. Insalaco, A. Martini, A. N. Olivieri, A. Ravelli, D. Rigante, E. Cortis, F. Corona, F. La Torre, F. Zulian, G. Conti, G. D'Angelo, L. Breda, M. C. Maggio, M. Cattalini, M. G. Alpigiani, M. Jorini, P. Barone, R. Cimaz, R. Consolini, R. Gallizzi, R. Podda, S. Davì, S. Pastore, S. Verazza, V. Gerloni   +27 more
core